News | May 03, 2024
Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Subscribe To Our Newsletter & Stay Updated
